Mouse Anti-CRADD Recombinant Antibody (CBYY-C2839) (V2LY-1206-LY1074)

Name: Mouse Anti-CRADD Recombinant Antibody (CBYY-C2839)
SKU: V2LY-1206-LY1074
Rating: 5 (1 reviews)

See all CRADD antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBYY-C2839

Application

WB, IF, IHC, ELISA

Immunogen

Recombinant CRADD (Met1-Glu199) expressed in E Coli.

Host Species

Mouse

Specificity

Human

Antibody Isotype

IgG2b, κ

Clonality

Monoclonal Antibody

Application Notes

Application	Note
ELISA	0.5-2 µg/ml
WB	0.5-2 µg/ml
IF(ICC)	5-20 µg/ml
IHC	5-20 µg/ml

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS

Preservative

None

Concentration

1 mg/ml

Purity

>95% as determined by analysis by SDS-PAGE

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

CASP2 and RIPK1 domain containing adaptor with death domain

Entrez Gene ID

8738

UniProt ID

P78560

Function

Adapter protein that associates with PIDD1 and the caspase CASP2 to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis (PubMed:9044836, PubMed:15073321, PubMed:16652156, PubMed:17159900, PubMed:17289572).

Also recruits CASP2 to the TNFR-1 signaling complex through its interaction with RIPK1 and TRADD and may play a role in the tumor necrosis factor-mediated signaling pathway (PubMed:8985253).

Biological Process

Activation of cysteine-type endopeptidase activity involved in apoptotic process Source: GO_Central
Apoptotic signaling pathway Source: UniProtKB
Cellular response to mechanical stimulus Source: UniProtKB
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest Source: UniProtKB
Extrinsic apoptotic signaling pathway via death domain receptors Source: BHF-UCL
Positive regulation of apoptotic process Source: UniProtKB
Positive regulation of apoptotic signaling pathway Source: GO_Central
Regulation of apoptotic process Source: Reactome

Cellular Location

Nucleus; Cytoplasm

Involvement in disease

Mental retardation, autosomal recessive 34, with variant lissencephaly (MRT34):
A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT34 is a non-syndromic form. Affected individuals have mildly delayed development and significantly impaired cognitive function, precluding independent living and self-care. Speech is rudimentary, but articulate; autism is not present.

Koprulu, M., Shabbir, R. M. K., Zaman, Q., Nalbant, G., Malik, S., & Tolun, A. (2021). CRADD and USP44 mutations in intellectual disability, mild lissencephaly, brain atrophy, developmental delay, strabismus, behavioural problems and skeletal anomalies. European Journal of Medical Genetics, 64(4), 104181.

Polla, D. L., Rahikkala, E., Bode, M. K., Määttä, T., Varilo, T., Loman, T., ... & Järvelä, I. (2020). Correction: Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish population. European Journal of Human Genetics, 28(4), 532-532.

Järvelä, I., Rahikkala, E., Bode, M. K., Varilo, T., & Norio, R. (2020). Suomalainen tautiperintö laajenee-aivojen paksupoimuisuutta aiheuttava CRADD-geenin mutaatio on rikastunut väestöömme. Duodecim.

Polla, D. L., Rahikkala, E., Bode, M. K., Määttä, T., Varilo, T., Loman, T., ... & Järvelä, I. (2019). Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish population. European Journal of Human Genetics, 27(8), 1235-1243.

Harel, T., Hacohen, N., Shaag, A., Gomori, M., Singer, A., Elpeleg, O., & Meiner, V. (2017). Homozygous null variant in CRADD, encoding an adaptor protein that mediates apoptosis, is associated with lissencephaly. American Journal of Medical Genetics Part A, 173(9), 2539-2544.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-CRADD Recombinant Antibody (CBYY-C2839)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-CRADD Recombinant Antibody (CBFYC-2186) (CAT#: V2LY-1206-LY1073)

Rabbit Anti-CRADD Recombinant Antibody (CBCNC-014) (CAT#: V2LY-1206-LY1071)

Mouse Anti-CRADD Recombinant Antibody (CBCNC-015) (CAT#: V2LY-1206-LY1072)

Mouse Anti-CRADD Recombinant Antibody (R0478) (CAT#: CBMAB-R0478-CN)

Mouse Anti-CRADD Recombinant Antibody (1F8) (CAT#: V2LY-1206-LY1069)

Mouse Anti-CRADD Recombinant Antibody (CBYCD-132) (CAT#: V2LY-1206-LY1068)

Human Recombinant RAIDD protein, His Tag (CAT#: V2LY-0526-LY6454)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry